Drugs Made In America Acquisition Corp. (DMAA): debt financing — DMAA SPAC enters $100K convertible bridge as first step of $500K financing; identifies AI/cybersecurity target

Drugs Made In America Acquisition Corp.

BV Advisory Partners provides $100K convertible note (up to $500K total) for compliance and transaction expenses.
Note converts at 35% discount to post-merger market value, matures in 6 months, no interest, no trust account claim.
Investor introduced potential target: enterprise AI/ML, quantum analytics, cybersecurity platform (Power Analytics Global).
Company to pursue replacement sponsor and provide investor ≥40% sponsor-level economics; no definitive agreement yet.
Proceeds used for audit, Nasdaq, legal, proxy, extension fees.

Key facts

Extracted from this filing and checked against the source text.

Debt Financings SEC 8-K Item 2.03/2.04 confidence 0.9

Drugs Made In America Acquisition Corp. incurred convertible notes of $100,000 with BV Advisory Partners, LLC at does not bear interest maturing six months from the date of issuance.

Instrument: convertible notes
Principal: $100,000
Counterparty: BV Advisory Partners, LLC
Rate: does not bear interest
Maturity: six months from the date of issuance
Event: incurrence

Exact text from the filing

On March 23, 2026, Drugs Made In America Acquisition Corp. (the " Company ") issued an interim convertible note (the " Interim Note ") to BV Advisory Partners, LLC (the " Investor ") in the principal amount of $100,000 (the " Interim Loan ").

View on SEC.gov

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.7

Drugs Made In America Acquisition Corp. entered into Investment Agreement with BV Advisory Partners, LLC valued at $500,000 (effective 2026-03-23).

Action: entry
Counterparty: BV Advisory Partners, LLC
Value: $500,000
Effective: 2026-03-23

Exact text from the filing

On March 23, 2026, Drugs Made In America Acquisition Corp. (the “ Company ”) issued an interim convertible note (the “ Interim Note ”) to BV Advisory Partners, LLC (the “ Investor ”) in the principal amount of $100,000 (the “ Interim Loan ”). The Interim Loan represents an initial loan towards a contemplated $500,000 financing (the “ Financing ”) pursuant to the Definitive Interim Investment and Sponsor Transition Agreement dated March 23, 2026 (the “ Investment Agreement ”)

View on SEC.gov

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Drugs Made In America Acquisition Corp. entered into Interim Note with BV Advisory Partners, LLC valued at $100,000 (effective 2026-03-23).

Action: entry
Agreement: notes offering
Counterparty: BV Advisory Partners, LLC
Value: $100,000
Effective: 2026-03-23

Exact text from the filing

issued an interim convertible note (the “ Interim Note ”) to BV Advisory Partners, LLC (the “ Investor ”) in the principal amount of $100,000

View on SEC.gov

40 debt financings filed in the last 30 days. Browse all debt financings →

Drugs Made In America Acquisition Corp. filing history →

Source: SEC EDGAR

accession 0001213900-26-035502

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.